COMMUNIQUÉS West-GlobeNewswire

Fortress Biotech Announces CAEL-101 Strategic Partnership with Alexion Pharmaceuticals

31/01/2019 - 12:30

Fortress-founded Caelum Biosciences to receive $60 million in a strategic equity investment and option fee Alexion has option to acquire Caelum Biosciences based on Phase 2 data NEW YORK, Jan. 31, 2019 (GLOBE NEWSWIRE [...]

Quotient Limited Provides an Update on Extended Immunohematology Microarray Performance and on the Commencement of the Initial Serological Disease Screening Field Trial together with Third Quarter Fiscal 2019 Results

31/01/2019 - 12:00

Development data provides positive results for extended IH microarray panel Field trial for initial Serological Disease microarray panel has commenced Reagent revenue growth of 15% in the quarter and 12% year to date [...]

Achillion Announces First Dosing in Phase 1 Multiple Ascending Dose Study of ACH-5228 Next-Generation Oral Factor D Inhibitor in Healthy Volunteers

31/01/2019 - 12:00

- ACH-5228, with improved potency and half-life, increases alternative pathway inhibition - - Achillion planning Investigational New Drug (IND) submission in fourth quarter of 2019 - NEW HAVEN, Conn., Jan. 31, 2019 ( [...]

Wright Medical Group N.V. Announces Privately Negotiated Exchange of Wright Medical Group, Inc.’s 2.00% Cash Convertible Senior Notes due 2020 for its 1.625% Cash Convertible Senior Notes due 2023

31/01/2019 - 12:00

AMSTERDAM, The Netherlands, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Wright Medical Group N.V. (NASDAQ: WMGI) (the “Company”) today announced that it has entered into privately negotiated agreements among the Company, Wright [...]

Business Development Director Lea Paloheimo will retire from Biohit Oyj

31/01/2019 - 11:00

Biohit Oyj 31.01.2019 at 12:00 local time (EST) Biohit’s management team member Business Development Director Lea Paloheimo will retire as planned 31 st of January 2019. Lea Paloheimo has been employed by Biohit since [...]

Registration of the quantity of shares in Nexstim Plc

31/01/2019 - 10:31

Company Announcement, Helsinki, 31.1.2019 at 11.30 Registration of the quantity of shares in Nexstim Plc The Extraordinary General Meeting of Nexstim Plc (NXTMH:HEX, NXTMS:STO), the targeted neuromodulation company [...]

Change to the Board of Directors

31/01/2019 - 10:00

Mrs. Patricia Malarkey resigns from the Board of Directors of Novozymes A/S. Read the full announcement in PDF. Attachment 2019_02_Change_to_the_BoD_EN

DrugCendR Announces Pancreatic Cancer Clinical Trial Data, New Member of Board of Directors and FDA Orphan Drug Designation

31/01/2019 - 09:31

LA JOLLA, Calif., Jan. 31, 2019 (GLOBE NEWSWIRE) -- DrugCendR Inc., a clinical-stage biopharmaceutical company dedicated to developing next generation cancer therapies designed to overcome the barriers of drug delivery [...]

Helsinn Provides Educational Grant for ESMO’s Preceptorship for Supportive and Palliative Care

31/01/2019 - 09:00

Helsinn Provides Educational Grant for ESMO’s Preceptorship for Supportive and Palliative Care Lugano, Switzerland, January 31, 2019 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care [...]

Capital increase of 26,060 shares (equivalent to approximately 0.13% of the existing shares) in Orphazyme A/S as a result of an issue of bonus shares to KLSDC and UCLB

31/01/2019 - 08:53

Orphazyme A/S Company announcement No. 03/2019 Company Registration No. 32266355 Copenhagen, Denmark, January 31 , 2019 – Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments [...]

Change in Number of Shares and Votes in Immunicum AB (publ) After Completed Rights Issue

31/01/2019 - 08:30

Press Release 31 January 2019 Change in Number of Shares and Votes in Immunicum AB (publ) After Completed Rights Issue Immunicum AB (publ) (the "Company" or "Immunicum") has, as previously announced, implemented a share [...]

Olainfarm will supply anti-tuberculosis drugs to the WHO for more than 1 million dollars

31/01/2019 - 08:20

Based on a cooperation agreement concluded last year, in the 1st quarter of 2019 JSC Olainfarm will be delivering its PAS- sodium anti-tuberculosis medicine, to the World Health Organisation (WHO) for a total of more [...]

Financière de Tubize SA : Cancellation of own shares - New denominator

31/01/2019 - 08:01

Press release 31st January 2019 - 8:00h CET FINANCIERE DE TUBIZE SA/NV Allée de la Recherche 60, 1070 Brussels Contact: Anne Sophie Pijcke, general manager, aspijcke@icloud.com Cancellation of own shares New denominator [...]

Financière de Tubize SA : Annulation d'actions propres - Nouveau dénominateur

31/01/2019 - 08:01

Communiqué de presse 31 janvier 2019 - 8:00h CET FINANCIERE DE TUBIZE SA Allée de la Recherche 60, 1070 Bruxelles Contact: Anne Sophie Pijcke, aspijcke@icloud.com Annulation d'actions propres Nouveau dénominateur [...]

Deinove is preparing initiation of Phase II for DNV3837 in Clostridium difficile infections, with a key partner

31/01/2019 - 08:00

Deinove is preparing initiation of Phase II for DNV3837 in Clostridium difficile infections, with a key partner The test design has been improved for a better assessment of DNV3837 effectiveness in treating Clostridium [...]

DEINOVE prépare l’entrée en Phase II du DNV3837 dans les infections à Clostridium difficile avec un partenaire-clé

31/01/2019 - 08:00

DEINOVE prépare l’entrée en Phase II du DNV3837 dans les infections à Clostridium difficile avec un partenaire-clé Le design de l’essai a été optimisé pour maximiser les chances de démontrer l’efficacité du DNV3837 dans [...]

Aladote®’s data has been selected for presentation at The International Liver Congress

31/01/2019 - 08:00

Stockholm, January 31, 2019. PledPharma AB (publ) announces that the abstract on the positive results from the Aladote ® ’s Phase Ib/IIa proof of principle-study has been selected for an oral presentation at the global [...]

Plan Stratégique Newway 2021

31/01/2019 - 08:00

NEWWAY 2021 Positionner Spineway comme acteur international de référence en mini-invasif Nouvelle politique commerciale Evolution des gammes de produits Partenariats stratégiques ciblés Spineway, spécialiste des [...]

Ambu A/S: Interim Report for Q1 2018/19

31/01/2019 - 07:58

In Q1, Ambu realised organic growth of 15% and a 43% increase in sales of endoscopes to 149,000 units. Gross profit increased by 1.9 percentage points to 59.9%, resulting in an EBIT margin of 17.1%. " In Q1, we have [...]